These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9475111)

  • 41. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological considerations in antiretroviral therapy.
    Sommadossi JP
    Antivir Ther; 1998; 3 Suppl 4():9-12. PubMed ID: 10723503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid.
    Takasawa K; Terasaki T; Suzuki H; Ooie T; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1509-17. PubMed ID: 9316866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prospects in the treatment of AIDS. II. AZT and related compounds; practical conclusions].
    Grieb P
    Pol Arch Med Wewn; 1992; 87(4-5):316-23. PubMed ID: 1381825
    [No Abstract]   [Full Text] [Related]  

  • 46. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients.
    Rolinski B; Bogner JR; Sadri I; Wintergerst U; Goebel FD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jul; 15(3):192-7. PubMed ID: 9257653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.
    Stain-Texier F; Boschi G; Sandouk P; Scherrmann JM
    Br J Pharmacol; 1999 Oct; 128(4):917-24. PubMed ID: 10556926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV in the brain: an interview with Dr. Michael Wool, UCLA researcher.
    Wool M
    Posit Dir News; 1998 Jan; 10(1):18-24. PubMed ID: 11365052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
    Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
    Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
    Zhou XJ; Havlir DV; Richman DD; Acosta EP; Hirsch M; Collier AC; Tebas P; Sommadossi JP;
    AIDS; 2000 Dec; 14(18):2869-76. PubMed ID: 11153668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study.
    Gibbs JE; Gaffen Z; Thomas SA
    J Pharmacol Exp Ther; 2006 May; 317(2):746-51. PubMed ID: 16424147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.
    Varatharajan L; Thomas SA
    Antiviral Res; 2009 May; 82(2):A99-109. PubMed ID: 19176219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.
    Cinque P; Bestetti A; Morelli P; Presi S
    J Neurovirol; 2000 May; 6 Suppl 1():S95-S102. PubMed ID: 10871772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.
    Saleh MAA; Loo CF; Elassaiss-Schaap J; De Lange ECM
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):725-741. PubMed ID: 34142308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The ins and outs of antiviral drug transport in the brain.
    Gallo JM
    J Neurovirol; 1997 Dec; 3(6):385-6. PubMed ID: 9475110
    [No Abstract]   [Full Text] [Related]  

  • 57. Central nervous system distribution kinetics of indinavir in rats.
    Hamidi M
    J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
    Wang X; Furukawa T; Nitanda T; Okamoto M; Sugimoto Y; Akiyama S; Baba M
    Mol Pharmacol; 2003 Jan; 63(1):65-72. PubMed ID: 12488537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Roles of hydrophobicity, protein binding and the probenecid-sensitive transport system in the cerebrospinal fluid delivery of nucleoside analogues with anti-viral activity.
    Kawaguchi T; Kusumi M; Hasegawa T; Nagata T; Saneyoshi M; Nakano M; Hamada A
    Biol Pharm Bull; 2000 Aug; 23(8):979-83. PubMed ID: 10963307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacology of antiretroviral drugs.
    Hoetelmans RM
    Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.